Kiromic BioPharma, Inc. focuses on developing advanced cell therapies, particularly leveraging its proprietary technology for CAR-T cell therapies aimed at treating various cancers. The company operates primarily in the U.S. biotechnology sector, with a competitive edge derived from its innovative approach to personalized medicine and a strong intellectual property portfolio.
Business Overview
Kiromic generates revenue through the development and commercialization of its CAR-T cell therapies. The company aims to capture value through partnerships with larger pharmaceutical firms and potential licensing agreements for its proprietary technologies, which provide a competitive advantage in personalized cancer treatment.
Clinical trial results for CAR-T therapies
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA
Market adoption rates of new therapies
Risk Factors
Regulatory changes that could impact approval processes for new therapies
Technological disruption from emerging competitors in the cell therapy space
Intense competition from established biotech firms with more resources
Emerging therapies that could outperform Kiromic's offerings
High operational cash burn rate leading to liquidity concerns
Potential for future capital raises which could dilute existing shareholders
Macro Sensitivity
moderate - The biotechnology sector can be sensitive to economic cycles, particularly in terms of funding for R&D and consumer spending on healthcare.
Higher interest rates may increase the cost of capital for Kiromic, affecting its ability to finance clinical trials and operations, potentially leading to a decrease in valuation multiples.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
Profile
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has shown significant volatility, with a recent 1-year return of -96.9%.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
